Chikungunya Virus Pathogenesis and Immunity

Vector-Borne and Zoonotic Diseases

Volumn 15, Issue 4, 2015, Pages 241-249

  Gasque, Philippe ^a   Couderc, Therese ^b,c   Lecuit, Marc ^b,c,d   Roques, Pierre ^e,f   Ng, Lisa F P ^g  

^a UNIVERSITÉ DE LA RÉUNION   (France)

^b INSTITUT PASTEUR   (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g AGENCY FOR SCIENCE   (Singapore)

Author keywords

Adaptive immunity; Chikungunya; Cytokines and chemokines; Inflammation; Innate immunity; Target cells

Indexed keywords

ACUTE DISEASE; ADAPTIVE IMMUNITY; ARBOVIRUS; ARTHRALGIA; ARTICLE; CHIKUNGUNYA; CHIKUNGUNYA VIRUS; CHRONIC DISEASE; CLINICAL FEATURE; EXPERIMENTAL ANIMAL; HUMAN; IMMUNITY; IMMUNOPATHOGENESIS; INFLAMMATION; INNATE IMMUNITY; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; VIRUS PATHOGENESIS; ANIMAL; DISEASE MODEL; IMMUNOLOGY; MOUSE; PATHOLOGY; PHYSIOLOGY; TRANSMISSION; ZOONOSIS;

ANIMALIA; ARBOVIRUS; CHIKUNGUNYA VIRUS;

CHEMOKINE; CYTOKINE;

ADAPTIVE IMMUNITY; ANIMALS; CHEMOKINES; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, INNATE; MICE; ZOONOSES;

EID: 84928596501     PISSN: 15303667     EISSN: 15577759     Source Type: Journal    
DOI: 10.1089/vbz.2014.1710     Document Type: Article

References (115)

1. Ahola T, Courderc T, Ng LFP, Hallengärd D, et al. Therapeutics and vaccines against chikungunya virus. Vector Borne Zoonotic Dis 2015; 15:250-257.
2. Akahata W, Yang ZY, Andersen H, Sun S, et al. A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat Med 2010; 16:334-338.
3. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4,:499-511.
4. Borgherini G, Poubeau P, Staikowsky F, Lory M, et al. Outbreak of chikungunya on Reunion Island: Early clinical and laboratory features in 157 adult patients. Clin Infect Dis 2007; 44:1401-1407.
5. Borgherini G, Poubeau P, Jossaume A, Gouix A, et al. Persistent arthralgia associated with chikungunya virus: A study of 88 adult patients on reunion island. Clin Infect Dis 2008; 47:469-475.
6. Borgherini G, Poubeau P, Paganin F. Chikungunya epidemic in Reunion Island. Epidemiol Infect 2009; 137:542-543; author reply 543.
7. Bouquillard E, Combe B. Rheumatoid arthritis after Chikungunya fever: A prospective follow-up study of 21 cases. Ann Rheum Dis 2009; 68:1505-1506.
8. Bréhin AC, Rubrecht L, Navarro-Sanchez ME, Maréchal V, et al. Production and characterization of mouse monoclonal antibodies reactive to Chikungunya envelope E2 glycoprotein. Virology 2008; 371:185-195.
9. Bréhin AC, Casademont I, Frenkiel MP, Julier C, et al. The large form of human 2′,5′-oligoadenylate synthetase (OAS3) exerts antiviral effect against Chikungunya virus. Virology 2009; 384:216-222.
10. Brighton SW, Simson IW. A destructive arthropathy following Chikungunya virus arthritis - a possible association. Clin Rheumatol 1984; 3:253-258.
11. Chang LJ, Dowd KA, Mendoza FH, Saunders JG, et al. VRC 311 Study Team. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: A phase 1 dose-escalation trial. Lancet 2014; 384:2046-2052.
12. Chen CI, Clark DC, Pesavento P, Lerche NW, et al. Comparative pathogenesis of epidemic and enzootic chikungunya viruses in a pregnant Rhesus macaque model. Am J Trop Med Hyg 2010; 83:1249-1258.
13. Chen W, Foo SS, Rulli NE, Taylor A, et al. Arthritogenic alphaviral infection perturbs osteoblast function and triggers pathologic bone loss. Proc Natl Acad Sci USA 2014a; 111:6040-6045.
14. Chen W, Foo S-S, Taylor A, Lulla A, et al. Bindarit, an inhibitor of monocyte chemotactic proteins (MCPs) synthesis, protects against bone loss induced by Chikungunya virus infection. J Virol 2014b; 89:581-593.
15. Chopra A, Anuradha V, Lagoo-Joshi V, Kunjir V, et al. Chikungunya virus aches and pains: An emerging challenge. Arthritis Rheum 2008; 58:2921-2922.
16. Chow A, Her Z, Ong EKS, Chen JM, et al. Persistent arthralgia induced by chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J Infect Dis 2011; 203:149-157.
17. Chu H, Das SC, Fuchs JF, Suresh M, et al. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine 2013; 31:3353-3360.
18. Couderc T, Chretien F, Schilte C, Disson O, et al. A mouse model for Chikungunya: Young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 2008;4:e29.
19. Couderc T, Khandoudi N, Grandadam M, Visse C, et al. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis 2009; 200:516-523.
20. Couderc T, Gangneux N, Chrétien F, Caro V, et al. Chikungunya virus infection of corneal grafts. J Infect Dis 2012; 206:851-859.
21. Economopoulou A, Dominguez M, Helynck B, Sissoko D, et al. Atypical Chikungunya virus infections: Clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on Reunion. Epidemiol Infect 2009; 137:534-541.
22. Fitzpatrick FA, Stringfellow DA. Virus and interferon effects on cellular prostaglandin biosynthesis. J Immunol 1980; 125:431-437.
23. Fourie ED, Morrison JG. Rheumatoid arthritic syndrome after chikungunya fever. S Afr Med J 1979; 56:130-132.
24. García-Arriaza J, Cepeda V, Hallengärd D, Sorzano CÓ, et al. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol 2014; 88:3527-3547.
25. Gardner J, Anraku I, Le TT, Larcher T, et al. Chikungunya virus arthritis in adult wild-type mice. J Virol 2010; 84:8021-8032.
26. Gérardin P. [Paediatric features of Dengue and Chikungunya fevers]. Arch Pediatr 2010; 17:86-90.
27. Gérardin P, Barau G, Michault A, Bintner M, et al. Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La Reunion. PLoS Med 2008; 5:e60.
28. Gérardin P, Samperiz S, Ramful D, Boumahni B, et al. Neurocognitive outcome of children exposed to perinatal mother-to-child chikungunya virus infection: The CHIMERE Cohort Study on Reunion Island. PLoS Negl Trop Dis 2014; 8:e2996.
29. Gifford GE, Heller E. Effect of actinomycin D on Interferon production by 'active' and 'inactive' chikungunya virus in chick Cells. Nature 1963; 200:50-51.
30. Grivard P, Le Roux K, Laurent P, Fianu A, et al. Molecular and serological diagnosis of Chikungunya virus infection. Pathol Biol (Paris) 2007; 55:490-494.
31. Hallengard D, Kakoulidou M, Lulla A, Kummerer BM, et al. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J Virol 2014; 88:2858-2866.
32. Harley D, Sleigh A, Ritchie S. Ross River virus transmission, infection, and disease: A cross-disciplinary review. Clin Microbiol Rev 2001; 14:909-932, table of contents.
33. Hawman DW, Stoermer KA, Montgomery SA, Pal P, et al. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. J Virol 2013; 87:13878-13888.
34. Her Z, Malleret B, Chan M, Ong EKS, et al. Active infection of human blood monocytes by Chikungunya virus triggers an innate immune response. J Immunol 2010; 184:5903-5913.
35. Her Z, Lum FM, Chow A, Leo YS, et al. Reply to Noret et al. J Infect Dis 2012; 206:457-459.
36. Her Z, Teng T-S, Tan JJ, Teo T-H, et al. Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response. EMBO Mol Med 2014; e201404459.
37. Higgs S, Ziegler SA. A nonhuman primate model of chikungunya disease. J Clin Invest 2010; 120:657-660.
38. Hoarau JJ, Bandjee MC, Trotot, PK, Das T, et al. Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol. 2010; 184:5914-5927.
39. Hoarau JJ, Gay F, Pelle O, Samri A, et al. Identical strength of the T cell responses against E2, nsP1 and capsid CHIKV proteins in recovered and chronic patients after the epidemics of 2005-2006 in La Reunion Island. PLoS One 2013; 8:e84695.
40. Judith D, Mostowy S, Bourai M, Gangneux N, et al. Species-specific impact of the autophagy machinery on chikungunya virus infection. EMBO Rep 2013; 14:534-544.
41. Kam Y, Ong EK, Rénia L, Tong JC, et al. Immuno-biology of chikungunya and implications for disease intervention. Microbes Infect 2009; 11:1186-1196.
42. Kam YW, Simarmata D, Chow A, Her Z, et al. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J Infect Dis 2012a; 205:1147-1154.
43. Kam YW, Lum FM, Teo TH, Lee WW, et al. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol Med 2012b; 4:330-343.
44. Kam YW, Lee WW, Simarmata D, Harjanto S, et al. Longitudinal analysis of the human antibody response to Chikungunya virus infection: Implications for serodiagnosis and vaccine development. J Virol 2012c; 86:13005-13015.
45. Kelvin AA, Banner D, Silvi G, Moro ML, et al. Inflammatory cytokine expression is associated with chikungunya virus resolution and symptom severity. PLoS Negl Trop Dis 2011; 5:e1279.
46. Krejbich-Trotot P, Denizot M, Hoarau JJ, Jaffar-Bandjee MC, et al. Chikungunya virus mobilizes the apoptotic machinery to invade host cell defenses. FASEB J 2011a; 25:314-325.
47. Krejbich-Trotot P, Gay B, Li-Pat-Yuen G, Hoarau JJ, et al. Chikungunya triggers an autophagic process which promotes viral replication. Virol J 2011b; 8:432.
48. Labadie K, Larcher T, Joubert C, Mannioui A, et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest 2010; 120:894-906.
49. Lakshmi V, Neeraja M, Subbalaxmi MV, Parida MM, et al. Clinical features and molecular diagnosis of Chikungunya fever from South India. Clin Infect Dis 2008; 46;1436-1442.
50. Laras K, Sukri NC, Larasati RP, Bangs MJ, et al. Tracking the re-emergence of epidemic chikungunya virus in Indonesia. Trans R Soc Trop Med Hyg 2005; 99:128-141.
51. Le Bomin A, Hebert JC, Marty P, Delaunay P. [Confirmed chikungunya in children in Mayotte. Description of 50 patients hospitalized from February to June 2006]. Med Trop (Mars) 2008; 68:491-495.
52. Lebrun G, Chadda K, Reboux AH, Martinet O, et al. Guillain-Barre syndrome after chikungunya infection. Emerg Infect Dis 2009; 15:495-496.
53. Lee CY, Kam YW, Fric J, Malleret B, et al. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. PLoS Pathog 2011; 7:e1002390.
54. Lemant J, Boisson V, Winer A, Thibault L, et al. Serious acute chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005-2006. Crit Care Med 2008; 36;2536-2541.
55. Leparc-Goffart I, Nougairède A, Cassadou S, Prat C, et al. Chikungunya in the Americas. Lancet 2014; 383:514.
56. Levine B, Hardwick JM, Griffin DE. Persistence of alphaviruses in vertebrate hosts. Trends Microbiol 1994; 2:25-28.
57. Lewthwaite P, Vasanthapuram R, Osborne JC, Begum A, et al. Chikungunya virus and central nervous system infections in children, India. Emerg Infect Dis 2009; 15:329-331.
58. Lum FM, Teo TH, Lee WW, Kam YW, et al. An essential role of antibodies in the control of Chikungunya virus infection. J Immunol 2013; 190:6295-6302.
59. Malfait A-M, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol 2013; 9:654-664.
60. Malvy D, Ezzedine K, Mamani-Matsuda M, Autran B, et al. Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies. BMC Infect Dis 2009; 9:200.
61. Manimunda SP, Vijayachari P, Uppoor R, Sugunan AP, et al. Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging. Trans R Soc Trop Med Hyg 2010; 104:392-399.
62. Mavalankar D, Shastri P, Raman P. Chikungunya epidemic in India: A major public-health disaster. Lancet Infect Dis 2007; 7:306-307.
63. Messaoudi I, Vomaske J, Totonchy T, Kreklywich CN, et al. Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity. PLoS Negl Trop Dis 2013; 7:e2343.
64. Metz SW, Martina BE, van den Doel P, Geertsema C, et al. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine 2013a; 31:6092-6096.
65. Metz SW, Gardner J, Geertsema C, Le TT, et al. Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl Trop Dis 2013b; 7:e2124.
66. Morens DM, Fauci AS. Chikungunya at the door - déjà vu all over again? N Engl J Med 2014; 371:885-887.
67. Morrison TE, Whitmore AC, Shabman RS, Lidbury BA, et al. Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J Virol 2006; 80:737-749.
68. Morrison TE, Oko L, Montgomery SA, Whitmore AC, et al. A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am J Pathol 2011; 178:32-40.
69. Morrison TE, Oko L, Montgomery SA, Whitmore AC, et al. A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: Evidence of arthritis, tenosynovitis, myositis, and persistence. Am J Pathol 2011; 178:32-40.
70. Nakaya HI, Gardner J, Poo Y-S, Major L, et al. Gene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis. Arthritis Rheum 2012; 64:3553-3563.
71. Ng LF, Chow A, Sun YJ, Kwek DJ, et al. IL-1beta, IL-6, and RANTES as biomarkers of Chikungunya severity. PLoS One 2009; 4:e4261.
72. Noret M, Herrero L, Rulli N, Rolph M, et al. Interleukin 6, RANKL, and osteoprotegerin expression by chikungunya virus-infected human osteoblasts. J Infect Dis 2012; 206:455-459.
73. Ozden S, Huerre M, Riviere JP, Coffey LL, et al. Human muscle satellite cells as targets of Chikungunya virus infection. PLoS One 2007; 2:e527.
74. Pal P, Dowd KA, Brien JD, Edeling MA, et al. Development of a highly protective combination monoclonal antibody therapy against chikungunya virus. PLoS Pathog 2013; 9:e1003312.
75. Panning M, Grywna K, van Esbroeck M, Emmerich P, et al. Chikungunya fever in travelers returning to Europe from the Indian Ocean region, 2006. Emerg Infect Dis 2008; 14:416-422.
76. Pellot AS, Alessandri JL, Robin S, Samperiz S, et al. [Severe forms of chikungunya virus infection in a pediatric intensive care unit on Reunion Island]. Med Trop (Mars) 2012; 72 Spec No:88-93.
77. Petitdemange C, Becquart P, Wauquier N, Beziat V, et al. Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog 2011; 7:e1002268.
78. Phuklia W, Kasisith J, Modhiran N, Rodpai E, et al. Osteoclastogenesis induced by CHIKV-infected fibroblast-like synoviocytes: A possible interplay between synoviocytes and monocytes/macrophages in CHIKV-induced arthralgia/arthritis. Virus Res 2013; 177:179-188.
79. Pialoux G, Gauzere BA, Jaureguiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis 2007; 7:319-327.
80. Poo Y-S. Understanding immunobiology of chikungunya virus disease using mouse models. PhD Thesis, School of Medicine, University of Queensland, 2014. doi:10.14264/uql.2014.261.
81. Poo Y-S, Nakaya H, Gardner J, Larcher T, et al. CCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated chikungunya virus arthritis. J Virol 2014a; 88:6862-6872.
82. Poo Y-S, Rudd PA, Gardner J, Wilson JAC, et al. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. PLoS Negl Trop Dis 2014b; 8:e3354.
83. Powers AM, Logue CH. Changing patterns of chikungunya virus: Re-emergence of a zoonotic arbovirus. J Gen Virol 2007; 88:2363-2377.
84. Prashant S, Kumar AS, Basheeruddin DD, Chowdhary TN, et al. Cutaneous manifestations in patients suspected of chikungunya disease. Indian J Dermatol 2009; 54:128-131.
85. Puiprom O, Morales Vargas RE, Potiwat R, Chaichana, P, et al. Characterization of chikungunya virus infection of a human keratinocyte cell line: role of mosquito salivary gland protein in suppressing the host immune response. Infect Genet Evol 2013; 17:210-215.
86. Ramful D, Carbonnier M, Pasquet M, Bouhmani B, et al. Mother-to-child transmission of chikungunya virus infection. Pediatr Infect Dis J 2007; 26:811-815.
87. Rao G, Khan YZ, Chitnis DS. Chikungunya infection in neonates. Indian Pediatr 2008; 45:240-242.
88. Ribera A, Degasne I, Jaffar Bandjee MC, Gasque P. [Chronic rheumatic manifestations following chikungunya virus infection: clinical description and therapeutic considerations]. Med Trop (Mars) 2012; 72 Spec No:83-85.
89. Rinaldo CR Jr, Overall JC Jr, Glasgow LA. Viral replication and interferon production in fetal and adult ovine leukocytes and spleen cells. Infect Immun 1975; 12:1070-1077.
90. Robillard PY, Boumahni B, Gérardin P, Michault A, et al. [Vertical maternal fetal transmission of the chikungunya virus. Ten cases among 84 pregnant women]. Presse Med 2006; 35:785-788.
91. Robin S, Ramful D, Le Seach F, Jaffar-Bandjee, MC, et al. Neurologic manifestations of pediatric chikungunya infection. J Child Neurol 2008; 23:1028-1035.
92. Robinson MC. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. Trans R Soc Trop Med Hyg 1955; 49:28-32.
93. Roques P, Gras G, Labadie K, Larcher T, et al. Chikungunya virus infection involved monocytes and during chronic phase of the disease persisted in tissue macrophages. 45th Annual Scientific Meeting of the European Society for Clinical Investigation. Crete, Greece, 13-16 April 2011. Eur J Clin Invest 2011; 41:23-52.
94. Roy CJ, Adams AP, Wang E, Plante K, et al. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. J Infect Dis 2014; 209:1891-1899.
95. Rudd PA, Wilson J, Gardner J, Larcher T, et al. Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock. J Virol 2012; 86:9888-9898.
96. Rulli NE, Rolph MS, Srikiatkhachorn A, Anantapreecha S, et al. Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis. J Infect Dis 2011; 204:1026-1030.
97. Schilte C, Couderc T, Chretien F, Sourisseau M, et al. Type I IFN controls chikungunya virus via its action on nonhematopoietic cells. J Exp Med 2010; 207:429-442.
98. Schilte C, Buckwalter MR, Laird ME, Diamond MS, et al. Cutting edge: Independent roles for IRF-3 and IRF-7 in hematopoietic and nonhematopoietic cells during host response to chikungunya infection. J immunol 2012; 188:2967-2971.
99. Schilte C, Staikowsky F, Couderc T, Madec Y, et al. Chikungunya virus-associated long-term arthralgia: A 36-month prospective longitudinal study. PLoS Negl Trop Dis 2013; 7:e2137.
100. Senanayake MP, Senanayake SM, Vidanage KK, Gunasena S, et al. Vertical transmission in chikungunya infection. Ceylon Med J 2009; 54:47-50.
101. Simon F, Parola P, Grandadam M, Fourcade S, et al. Chikungunya infection: An emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases. Medicine (Baltimore) 2007; 86:123-137.
102. Sissoko D, Malvy D, Ezzedine K, Renault P, et al. Post-epidemic chikungunya disease on Reunion Island: Course of rheumatic manifestations and associated factors over a 15-month period. PLoS Negl Trop Dis 2009; 3:e389.
103. Sourisseau M, Schilte C, Casartelli N, Trouillet C, et al. Characterization of reemerging chikungunya virus. PLoS Pathog 2007; 3:e89.
104. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity 2006; 25:373-381.
105. Suhrbier A, La Linn M. Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Curr Opin Rheumatol 2004; 16:374-379.
106. Teng TS, Foo SS, Simamarta D, Lum FM, et al. Viperin restricts chikungunya virus replication and pathology. J Clin Invest 2012; 122:4447-4460.
107. Teo TH, Lum FM, Claser C, Lulla V, et al. An essential role of antibodies in the control of Chikungunya virus infection. J Immunol 2013; 190:6295-6302.
108. Tesh RB. Arthritides caused by mosquito-borne viruses. Annu Rev Med 1982; 33:31-40.
109. Thangamani S, Higgs S, Ziegler S, Vanlandingham D, et al. Host immune response to mosquito-transmitted chikungunya virus differs from that elicited by needle inoculated virus. PLoS One 2010; 5:e12137.
110. Thon-Hon VG, Denizot M, Li-Pat-Yuen G, Giry C, et al. Deciphering the differential response of two human fibroblast cell lines following chikungunya virus infection. Virol J 2012; 9:213.
111. Toivanen A. Alphaviruses: An emerging cause of arthritis? Curr Opin Rheumatol 2008; 20:486-490.
112. Valamparampil JJ, Chirakkarot S, Letha S, Jayakumar C, et al. Clinical profile of Chikungunya in infants. Indian J Pediatr 2009; 76:151-155.
113. van den Doel P, Volz A, Roose JM, Sewbalaksing VD, et al. Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of chikungunya virus protects AG129 mice against lethal challenge. PLoS Negl Trop Dis 2014; 8:e3101.
114. Wauquier N, Becquart P, Nkoghe D, Padilla C, et al. The acute phase of chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation. J Infect Diseases 2011; 204:115-123.
115. Ziegler SA, Lu L, da Rosa AP, Xiao SY, et al. An animal model for studying the pathogenesis of chikungunya virus infection. Am J Trop Med Hyg 2008; 79:133-139.